In breast cancer cells and xenograft breast cancer models, methylation of EGFR by PRMT5 promotes breast cancer cellular proliferation and tumour progression through activation of the ERK-mediated oncogenic pathway25. Here, PRMT5 is linked to breast carcinoma.